KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) EBIT Margin (2020 - 2023)

Historic EBIT Margin for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to 719.61%.

  • AbCellera Biologics' EBIT Margin fell 5442700.0% to 719.61% in Q4 2023 from the same period last year, while for Dec 2023 it was 623.8%, marking a year-over-year decrease of 6684000.0%. This contributed to the annual value of 1091.69% for FY2024, which is 4678700.0% down from last year.
  • AbCellera Biologics' EBIT Margin amounted to 719.61% in Q4 2023, which was down 5442700.0% from 831.79% recorded in Q3 2023.
  • AbCellera Biologics' 5-year EBIT Margin high stood at 77.97% for Q1 2021, and its period low was 831.79% during Q3 2023.
  • In the last 4 years, AbCellera Biologics' EBIT Margin had a median value of 22.16% in 2020 and averaged 192.1%.
  • In the last 5 years, AbCellera Biologics' EBIT Margin skyrocketed by 5473100bps in 2022 and then plummeted by -8690100bps in 2023.
  • Quarter analysis of 4 years shows AbCellera Biologics' EBIT Margin stood at 77.33% in 2020, then dropped by -24bps to 58.53% in 2021, then plummeted by -400bps to 175.34% in 2022, then crashed by -310bps to 719.61% in 2023.
  • Its EBIT Margin stands at 719.61% for Q4 2023, versus 831.79% for Q3 2023 and 511.03% for Q2 2023.